Bruce Dopler, MD
Neurology · Seaford, DENPI 1992860027
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 223 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 13.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,190 and has fallen 50.6% since, to $589 in 2025.
Across 223 payments — averaging $16.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$494
- Lilly USA, LLC$409
- Amneal Pharmaceuticals LLC$390
- AbbVie$334
- Biogen$233
- Novartis$190
- plus $2K from 28 others
What the payments were for
- Food & beverage$3,713100%
- Education$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 52 | $494 |
| Lilly USA, LLC | 23 | $409 |
| Amneal Pharmaceuticals LLC | 21 | $390 |
| AbbVie | 28 | $334 |
| Biogen | 13 | $233 |
| Novartis | 11 | $190 |
| UCB, Inc. | 9 | $160 |
| Lundbeck LLC | 7 | $157 |
| Genentech USA, Inc. | 3 | $127 |
| Bristol Myers Squibb | 7 | $121 |
| Teva Pharmaceuticals USA, Inc. | 4 | $117 |
| Amgen | 5 | $102 |
| Penumbra, Inc. | 1 | $87 |
| Life Molecular Imaging Ltd | 4 | $86 |
| Sumitomo Pharma America, Inc. | 7 | $83 |
| Eisai Inc. | 3 | $80 |
| Abbott | 1 | $67 |
| Medtronic(2 entities) | 2 | $52 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $50 |
| GE HealthCare | 2 | $41 |
| Neurelis, Inc. | 2 | $39 |
| EMD Serono, Inc. | 2 | $38 |
| Argenx US, Inc. | 2 | $38 |
| Otsuka America Pharmaceutical, Inc. | 2 | $35 |
| Catalyst Pharmaceuticals, Inc. | 2 | $29 |
| Azurity Pharmaceuticals, Inc. | 1 | $24 |
| Octapharma USA, Inc. | 1 | $23 |
| Cycle Pharmaceuticals Inc | 1 | $21 |
| AstraZeneca | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Acadia Pharmaceuticals Inc | 1 | $16 |
| Johnson & Johnson | 1 | $16 |
| Insightec,inc | 1 | $16 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$3,726 in reported general payments places this provider in the 75th percentile of 61 neurology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GammakedImmune Globul G/Gly/Iga Avg 46 | 14 | $501,230 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 42 | $459,703 |
| BetaseronInterferon Beta-1b | 13 | $144,303 |
| NuplazidPimavanserin Tartrate | 19 | $140,198 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 14 | $116,311 |
| RexultiBrexpiprazole | 43 | $102,090 |
| GlatopaGlatiramer Acetate | 16 | $71,779 |
| EliquisApixaban | 58 | $71,202 |
| Droxidopa | 38 | $65,850 |
| XareltoRivaroxaban | 42 | $49,930 |
| AmpyraDalfampridine | 11 | $48,120 |
| BriviactBrivaracetam | 14 | $34,897 |
| RytaryCarbidopa/Levodopa | 52 | $30,599 |
| BotoxOnabotulinumtoxina | 17 | $25,475 |
| NamzaricMemantine Hcl/Donepezil Hcl | 27 | $24,583 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $16 | $140,19819 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $35 | $102,09043 claims |
| PfizerEliquis, Nurtec Odt | $494 | $91,02269 claims |
| AbbVieBotox, Namzaric, Qulipta | $334 | $61,61655 claims |
| Johnson & JohnsonXarelto | $16 | $49,93042 claims |
| UCB, Inc.Briviact | $160 | $34,89714 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $390 | $33,08493 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 61 neurology providers in Delaware.
Other neurology in Seaford
- Raju MaharjanSeaford$6K
- Gina AldersonSeaford$3K
- Justin MartelloNewark$485K
- Abraham ScheerDover$231K
- Jason SilversteenNewark$202K
- Jay DaveMilford$161K
- Lawrence KempLewes$24K
- Etsegenet TizazuNewark$15K
- William SommersNewark$14K
- Lee DresserNewark$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.